MGF (Mechano Growth Factor, IGF-1Ec) is a research-stage compound and is not an FDA-approved medicine. This page describes hypothesized and investigational effects drawn largely from preclinical work, not established treatments.
Overview
MGF is a splice variant of IGF-1 produced locally within muscle after mechanical loading and damage. Because of this mechanism, most interest in MGF centres on:
- Its hypothesized role in the early stages of muscle repair.
- Proposed activation of satellite cells, the muscle stem cells involved in regeneration.
- Its distinction from liver-derived systemic IGF-1.
These are the mechanisms researchers study in cell and animal models; they are not a promise of any specific cosmetic, athletic, or clinical result in humans.
Muscle repair and satellite cells
The central research theme for MGF is its proposed involvement in the early response to muscle stress. In preclinical work, it has been studied for its hypothesized ability to activate and encourage proliferation of satellite cells ahead of the more sustained signaling attributed to systemic IGF-1.
- Findings come mostly from cell and animal models rather than human trials.
- How this early signaling contributes to net repair in people is uncertain.
- Effect size and reproducibility remain open research questions.
Local versus systemic action
A defining feature of MGF is that it is expressed locally in loaded muscle rather than circulating widely like systemic IGF-1. This local, short-lived nature is a recurring theme in the literature and is part of why MGF is studied as a distinct entity rather than as a substitute for systemic IGF-1.
How MGF compares to related peptides
MGF is often discussed alongside related growth-factor compounds, each with a different profile:
- Systemic IGF-1 — the circulating, liver-derived form with broader, more sustained signaling.
- PEG-MGF — a pegylated version engineered for greater stability and a longer presence in circulation.
Native MGF is generally described as short-acting compared with PEG-MGF, which is one reason the pegylated variant was developed.
Evidence and caveats
MGF has interesting preclinical biology, but that is not the same as proven benefit for muscle, recovery, or performance in humans. Key caveats:
- It is not an FDA-approved therapy.
- Most data are from cell and animal models, not controlled human trials.
- It is frequently confused with systemic IGF-1 and with PEG-MGF.
- Long-term safety in people has not been established.